NEW YORK – Bio-Rad Laboratories and Qiagen have agreed to settle a patent dispute pending in the US District Court for the District of Delaware, the firms announced on Wednesday.
The court settlement is pursuant to a global settlement and patent cross-licensing agreement related to digital PCR technology, Bio-Rad and Qiagen said in separate identical statements.
The patents that were the subject of the dispute are either assigned to or licensed by Bio-Rad and relate to digital PCR or cell capture methods used in digital PCR.
The settlement now grants each company mutual rights to their respective digital PCR technologies, Bio-Rad and Qiagen said.
Qiagen, meanwhile, launched the QIAcuity digital PCR system in Europe in 2020. It filed suit against Bio-Rad last year seeking a declaration of non-infringement on digital PCR patents after receiving letters from Bio-Rad asserting the technology infringed on Bio-Rad's patented methods.